CN108514550A - Solid drugs and preparation method thereof containing Abiraterone acetate - Google Patents
Solid drugs and preparation method thereof containing Abiraterone acetate Download PDFInfo
- Publication number
- CN108514550A CN108514550A CN201810317137.8A CN201810317137A CN108514550A CN 108514550 A CN108514550 A CN 108514550A CN 201810317137 A CN201810317137 A CN 201810317137A CN 108514550 A CN108514550 A CN 108514550A
- Authority
- CN
- China
- Prior art keywords
- parts
- abiraterone acetate
- solid composite
- composite medicament
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to field of pharmaceutical preparations, and in particular to a kind of solid drugs and preparation method thereof containing Abiraterone acetate.Solid composite medicament containing Abiraterone acetate contains Abiraterone acetate, lauryl sodium sulfate and pharmaceutically acceptable auxiliary material；The Abiraterone acetate accounts for the 35.0 62.5% of solid composite medicament total weight.The solid drugs containing Abiraterone acetate of the present invention solve the problems such as current product drugloading rate is low, auxiliary material proportion is high, tablet volume is larger, improve the compliance of clinically patient's medication；The present invention prepares Abiraterone acetate solid drugs using the method for fluid-bed marumerization, simplify preparation process, shorten time of the main ingredient in hot and humid environment, be conducive to the magazine control of this product, improve product quality, the method of the present invention is suitable for industrialized production, there is larger application value.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, and in particular to a kind of solid drugs containing Abiraterone acetate and its preparation
Method.
Background technology
Abiraterone is invented by the researcher of the British royal Marsden hospital positioned at the London west and south, which is
17 α of key enzyme -17 α of hydroxylase-C17,2- lyase-monooxygenase inhibitor or human-cytochrome in male sex hormone synthesis
Effective selection oral inhibitor of P45017 α, by inhibiting the key enzyme in androgen synthesis --- CYP450c17 by, reduces hero
Hormonal readiness, and have inhibiting effect to the androgen of testis and other positions of body.At present in prostate cancer patients
Proof can inhibit male sex hormone with Abiraterone acetate, be a kind of white to pale, nonhygroscopic crystal powder, and molecular formula is
C26H33NO2, structural formula sees below formula, molecular weight 391.55.
Abiraterone acetate is a kind of lipophilic compound, and octanol-water partition coefficient 5.12 (Log P) does not dissolve in especially
Water.Therefore dissolution rate is to need the technical barrier solved in the research of Abiraterone acetate tablet.The prior art is for solving acetic acid
The indissoluble sex chromosome mosaicism preparation method of abiraterone piece is in Chinese patent CN103446069, CN102743393, CN103070828
It is described.Method disclosed in wherein CN103446069 is to carry out micronization processes, control using by Abiraterone acetate bulk pharmaceutical chemicals
Grain size improves Dissolution of Tablet in 0-20 μ ms, but finds that individually micronizing can not be obviously improved bulk pharmaceutical chemicals after studying
Dissolution, and be crushed to the particle size range and need special installation；Method disclosed in CN102743393 be using bulk pharmaceutical chemicals and lactose,
The hydrophilicity condiments such as starch carry out the method for total crushing to improve dissolution, while adding after surfactant is mixed with adhesive
Enter, since the dosage of adhesive is unfixed, the dosage of surfactant can be caused to be not fixed in practical operation, cause to influence
Dissolution rate it is inconsistent；And CN103070828 is then the method for preparing solid dispersions with povidone using Abiraterone acetate
The problems such as improving dissolution, but preparing the methods of solid dispersions that there are technological operations is cumbersome, stability is poor.
Current Abiraterone acetate solid drugs there are drugloading rates it is low, auxiliary material proportion is high, tablet volume is larger the problems such as,
Preparation method is cumbersome, it is therefore desirable to develop a kind of raising drugloading rate, reduce tablet volume, improve clinically patient's medication
Compliance and preparation method is simple, the high preparation method suitable for industrialized production of product quality.
Invention content
In view of this, the purpose of the present invention is to provide a kind of solid composite medicament and profit containing Abiraterone acetate
The method for preparing Abiraterone acetate solid drugs with solid composite medicament, vinegar prepared by solid composite medicament of the invention
Drugloading rate can be improved in sour abiraterone preparation medicine, reduces tablet volume, improves the compliance of clinically patient's medication.
To achieve the above object, the technical scheme is that：
Solid composite medicament containing Abiraterone acetate contains Abiraterone acetate, lauryl sodium sulfate and medicine
Acceptable auxiliary material on；The Abiraterone acetate accounts for the 35.0-62.5% of solid composite medicament total weight.
It is ellipse slice that Abiraterone acetate piece original, which grinds product, and tablet volume is larger, major diameter about 1.6cm, minor axis about 1cm,
For patients, dysphagia.To find out its cause, since this product active constituent mobility, compressibility are poor, solubility is relatively low,
And original grinds product and uses wet granulation technology, in order to which mobility, the preferable particle of compressibility is made, with constantly product dissolution rate
Meet demand, need in prescription using a large amount of auxiliary material come make up bulk pharmaceutical chemicals mobility, compressibility, solubility etc. no
Foot, it is 715mg that original, which grinds product single tablet weight, wherein the only 250mg containing active constituent, the remaining equal auxiliary materials of 465mg.The present invention's
Abiraterone acetate proportion can reach 62.5% in solid composite medicament containing Abiraterone acetate, the acetic acid of preparation
Drugloading rate can be improved in abiraterone preparation medicine, substantially reduces tablet volume, and patient swallows more easily, and raising is clinically suffered from
The compliance of person's medication.
Further, the weight ratio of the Abiraterone acetate and lauryl sodium sulfate is 35.0-62.5：0.5-1.5.
Further, the pharmaceutically acceptable auxiliary material includes filler, disintegrant, adhesive and lubricant.
Further, the filler includes lactose monohydrate, microcrystalline cellulose, mannitol, sorbierite, cornstarch, pre- glue
Change one or more in starch；The disintegrant includes croscarmellose sodium, sodium carboxymethyl starch, crospovidone
In it is one or more；Described adhesive include povidone, hydroxypropyl methylcellulose it is one or more；The lubricant includes hard
It is one or more in fatty acid magnesium, colloidal silicon dioxide and sodium stearyl fumarate.
As a preferred embodiment, the filler is lactose monohydrate and microcrystalline cellulose；The disintegrant is cross-linked carboxymethyl
Sodium cellulosate；Described adhesive is povidone or hydroxypropyl methylcellulose；The lubricant is magnesium stearate and colloidal silicon dioxide.
Further, the solid composite medicament includes following components by weight：Abiraterone acetate 35.0-62.5
Part, 15.0-30.0 parts of lactose monohydrate, 10.0-25.0 parts of microcrystalline cellulose, 1.0-4.0 parts of croscarmellose sodium, 12
0.5-1.5 parts of sodium alkyl sulfate, 2.0-5.0 parts of povidone or 1.0-3.0 parts of hydroxypropyl methylcellulose, colloidal silicon dioxide 0.25-
2.0 parts and 0.2-1.0 parts of magnesium stearate.
Further, the solid composite medicament includes following components by weight：Abiraterone acetate 45.0-62.5
Part, 20.0-30.0 parts of lactose monohydrate, 10.0-25.0 parts of microcrystalline cellulose, 1.5-4.0 parts of croscarmellose sodium, 12
1-1.5 parts of sodium alkyl sulfate, 2.5-5.0 parts of povidone or 1.5-3.0 parts of hydroxypropyl methylcellulose, colloidal silicon dioxide 0.25-1.5
0.2-0.5 parts of part and magnesium stearate.
As a preferred embodiment, the solid composite medicament includes following components by weight：Abiraterone acetate
52.5 parts, 24.0 parts of lactose monohydrate, 15.5 parts of microcrystalline cellulose, 2.5 parts of croscarmellose sodium, lauryl sodium sulfate
0.4 part of 2.3 parts of 1.25 parts, 3.0 parts of povidone or hydroxypropyl methylcellulose, 1.0 parts of colloidal silicon dioxide and magnesium stearate.
Further, the solid composite medicament can be prepared as Abiraterone acetate tablet, granule or capsule.
The second object of the present invention is to provide a kind of preparing Abiraterone acetate using above-mentioned solid composite medicament
The method of solid drugs, includes the following steps：
1) povidone of above-mentioned parts by weight or hydroxypropyl methylcellulose, lauryl sodium sulfate are added fully molten in aqueous medium
Solution；
It 2) will micronizing Abiraterone acetate, recipe quantity 60-100% microcrystalline celluloses, recipe quantity 60-100% crosslinking carboxylics
Sodium carboxymethylcellulose pyce, lactose are sieved with 100 mesh sieve and are mixed, and obtain mixed material；
3) the step 2) mixed material is further mixed and added at 40-60 DEG C containing povidone or hydroxypropyl methylcellulose
With the purification of aqueous solutions of lauryl sodium sulfate；
4) by dry particl obtained above by 24-60 mesh sieve carry out whole grain, be added prescription surplus microcrystalline cellulose and
Croscarmellose sodium, colloidal silicon dioxide simultaneously add magnesium stearate lubricant and uniformly mix again after being sufficiently mixed uniformly
It closes, tabletting obtains Abiraterone acetate piece.
Further, step 3) is specially：Step 2) the mixed material addition is pre-heated to 40-60 DEG C of fluid bed one
It walks in granulator pot body, opening wind turbine and heating makes material further be uniformly mixed, and keeps temperature of charge constant to 40-60 DEG C,
Then start to pelletize, air quantity is 30-50Hz when granulation, is sprayed into containing povidone or hydroxypropyl methylcellulose and 12 with the mode of spraying
The purification of aqueous solutions of sodium alkyl sulfate is pelletized and is dried；
Further, spray velocity 60rpm, atomisation pressure 2.0bar；Wind turbine frequency is 35-45Hz, material when dry
30-70 DEG C of temperature, 60-100 DEG C of inlet air temperature, drying to moisture are 1.0-3.0%.
Preparation process is simplified using the method for fluid-bed marumerization, shorten main ingredient in hot and humid environment when
Between, be conducive to the magazine control of this product, improve product quality.
The beneficial effects of the present invention are：
1) Abiraterone acetate proportion can reach in the solid composite medicament containing Abiraterone acetate of the invention
To 62.5%, solves the problems such as current product drugloading rate is low, auxiliary material proportion is high, tablet volume is larger；The solid medicine of the present invention
Drugloading rate can be improved in Abiraterone acetate preparation medicine prepared by compositions, substantially reduces tablet volume, patient swallows
More easily, the compliance of clinically patient's medication is improved.
2) present invention prepares Abiraterone acetate solid drugs using the method for fluid-bed marumerization, simplifies preparation step
Suddenly, time of the main ingredient in hot and humid environment is shortened, is conducive to the magazine control of this product, improves product quality.This hair
Bright method is suitable for industrialized production, there is larger application value.
Description of the drawings
Fig. 1 is drug sample defects inspecting situation schematic diagram prepared by the present invention.
Specific implementation mode
It detailed description of a preferred embodiment of the present invention will be given below.The reality of actual conditions is not specified in preferred embodiment
Proved recipe method, usually according to normal condition, illustrated embodiment are but not to be to preferably be illustrated to present disclosure
Present disclosure is only limitted to illustrated embodiment.So those skilled in the art according to foregoing invention content to embodiment party
Case carries out nonessential modifications and adaptations, still falls within protection scope of the present invention.
Embodiment 1
Solid composite medicament prescription
Embodiment 2
Solid composite medicament prescription
| Ingredient | Proportion (%, w/w) |
| Abiraterone acetate | 60.5 |
| Lactose monohydrate | 17 |
| Microcrystalline cellulose | 13.8 |
| Croscarmellose sodium | 3.5 |
| Lauryl sodium sulfate | 1.2 |
| Hydroxypropyl methylcellulose | 2.5 |
| Colloidal silicon dioxide | 0.5 |
| Magnesium stearate | 1.0 |
Embodiment 3
Solid composite medicament prescription
| Ingredient | Proportion (%, w/w) |
| Abiraterone acetate | 52.5 |
| Lactose monohydrate | 26.0 |
| Microcrystalline cellulose | 15.0 |
| Croscarmellose sodium | 2.6 |
| Lauryl sodium sulfate | 0.8 |
| Povidone | 1.5 |
| Colloidal silicon dioxide | 1.0 |
| Magnesium stearate | 0.6 |
Embodiment 4
Solid composite medicament prescription
| Ingredient | Proportion (%, w/w) |
| Abiraterone acetate | 35.0 |
| Lactose monohydrate | 30.0 |
| Microcrystalline cellulose | 22.5 |
| Croscarmellose sodium | 4.0 |
| Lauryl sodium sulfate | 1.5 |
| Povidone | 5.0 |
| Colloidal silicon dioxide | 0.5 |
| Magnesium stearate | 1.0 |
Embodiment 5
The method for preparing Abiraterone acetate solid drugs using above-mentioned solid composite medicament, includes the following steps：
1. povidone or hydroxypropyl methylcellulose, lauryl sodium sulfate are added in purified water, dissolving is complete, spare；
2. will micronizing Abiraterone acetate, recipe quantity 60-100% microcrystalline celluloses, recipe quantity 60-100% crosslinking carboxylics
Sodium carboxymethylcellulose pyce, lactose sieve with 100 mesh sieve removal agglomerate and tentatively mix；
3. the addition of said mixture material is pre-heated in 40-60 DEG C of fluid-bed marumerization machine pot body, wind turbine is opened
And heating makes material further be uniformly mixed, and keeps temperature of charge constant to 40-60 DEG C, then starts to pelletize, air quantity when granulation
For 30-50Hz, the purification of aqueous solutions containing povidone (or hydroxypropyl methylcellulose) and lauryl sodium sulfate is sprayed into, spray velocity is
60rpm, atomisation pressure 2.0bar, wind turbine frequency is 35-45Hz, 30-70 DEG C of temperature of charge, inlet air temperature 60-100 when dry
DEG C, drying to moisture is 1.0-3.0%；
4. above-mentioned dry particl is sieved by 24-60 mesh and carries out whole grain, prescription surplus microcrystalline cellulose and crosslinking carboxylic is added
Sodium carboxymethylcellulose pyce, colloidal silicon dioxide are simultaneously sufficiently mixed uniformly in mixing machine；
5. magnesium stearate lubricant is added into above-mentioned material and mixes again；
6. carrying out tabletting with high speed rotary tablet press, aluminum-plastic packaged finished product Abiraterone acetate piece is finally carried out.
Embodiment 6
Drug prepared by the present invention carries out Quality Detection, testing result：
Sample defects inspecting situation is as shown in table 1 and Fig. 1：
Drug prepared by 1 present invention of table and detection of the comparison medicine in relation to substance
* remarks：Impurity ＜ 0.05% is less than quantitative limit, is identified as and is not detected
The present invention prepares sample no matter in impurity number and size, is superior to list preparation, product quality is more preferable.
2 inventive samples of table and dissolution data of the comparison medicine in different medium
The present invention prepares sample, in a variety of media dissolution degree and rate with to have listed formulation consistency degree higher,
Strong guarantee is unanimously provided for product curative effect.
Finally illustrate, the above examples are only used to illustrate the technical scheme of the present invention and are not limiting, although with reference to compared with
Good embodiment describes the invention in detail, it will be understood by those of ordinary skill in the art that, it can be to the skill of the present invention
Art scheme is modified or replaced equivalently, and without departing from the objective and range of technical solution of the present invention, should all be covered at this
In the right of invention.
Claims (10)
1. the solid composite medicament containing Abiraterone acetate, which is characterized in that contain Abiraterone acetate, dodecyl sulphur
Sour sodium and pharmaceutically acceptable auxiliary material；The Abiraterone acetate accounts for the 35.0- of solid composite medicament total weight
62.5%.
2. solid composite medicament according to claim 1, which is characterized in that the Abiraterone acetate and dodecyl
The weight ratio of sodium sulphate is 35.0-62.5：0.5-1.5.
3. solid composite medicament according to claim 1, which is characterized in that the pharmaceutically acceptable auxiliary material includes
Filler, disintegrant, adhesive and lubricant.
4. solid composite medicament according to claim 3, which is characterized in that the filler includes lactose monohydrate, micro-
It is one or more in crystalline cellulose, mannitol, sorbierite, cornstarch, pregelatinized starch；The disintegrant includes crosslinking carboxylic
It is one or more in sodium carboxymethylcellulose pyce, sodium carboxymethyl starch, crospovidone；Described adhesive includes povidone, hydroxypropyl
Methylcellulose it is one or more；The lubricant includes in magnesium stearate, colloidal silicon dioxide and sodium stearyl fumarate
It is one or more.
5. according to claim 1-4 any one of them solid composite medicaments, which is characterized in that include with the following group by weight
Point：35.0-62.5 parts of Abiraterone acetate, 15.0-30.0 parts of lactose monohydrate, 10.0-25.0 parts of microcrystalline cellulose, crosslinking carboxylic first
1.0-4.0 parts of base sodium cellulosate, 0.5-1.5 parts of lauryl sodium sulfate, 2.0-5.0 parts of povidone or hydroxypropyl methylcellulose 1.0-
0.2-1.0 parts of 3.0 parts, 0.25-2.0 parts of colloidal silicon dioxide and magnesium stearate.
6. solid composite medicament according to claim 5, which is characterized in that include following components by weight：Acetic acid
45.0-62.5 parts of abiraterone, 20.0-30.0 parts of lactose monohydrate, 10.0-25.0 parts of microcrystalline cellulose, cross-linked carboxymethyl fiber
Plain sodium 1.5-4.0 parts, 1-1.5 parts of lauryl sodium sulfate, 2.5-5.0 parts of povidone or 1.5-3.0 parts of hydroxypropyl methylcellulose, glue
0.2-0.5 parts of 0.25-1.5 parts of state silica and magnesium stearate.
7. according to claim 1-4 any one of them solid composite medicaments, which is characterized in that the solid composite medicament
It can be prepared as Abiraterone acetate tablet, granule or capsule.
8. the method for preparing Abiraterone acetate solid drugs using the solid composite medicament described in claim 5, feature
It is, includes the following steps：
1) povidone of above-mentioned parts by weight or hydroxypropyl methylcellulose, lauryl sodium sulfate are added in aqueous medium and are fully dissolved；
It 2) will micronizing Abiraterone acetate, recipe quantity 60-100% microcrystalline celluloses, recipe quantity 60-100% cross-linked carboxymethyls
Sodium cellulosate, lactose are sieved with 100 mesh sieve and are mixed, and obtain mixed material；
3) the step 2) mixed material is further mixed and added at 40-60 DEG C containing povidone or hydroxypropyl methylcellulose and ten
The purification of aqueous solutions of sodium dialkyl sulfate；
4) dry particl obtained above is sieved by 24-60 mesh and carries out whole grain, prescription surplus microcrystalline cellulose and crosslinking is added
Sodium carboxymethylcellulose, colloidal silicon dioxide and be sufficiently mixed uniformly after add magnesium stearate lubricant again uniformly mixing,
Tabletting obtains Abiraterone acetate piece.
9. according to the method described in claim 8, it is characterized in that, step 3) is specially：Step 2) the mixed material is added
Enter to be pre-heated in 40-60 DEG C of fluid-bed marumerization machine pot body, opening wind turbine and heating makes material further be uniformly mixed,
And keep temperature of charge constant to 40-60 DEG C, then start to pelletize, air quantity is 30-50Hz when granulation, is sprayed into and is contained with the mode of spraying
Povidone or hydroxypropyl methylcellulose and the purification of aqueous solutions of lauryl sodium sulfate are pelletized and are dried.
10. according to the method described in claim 9, it is characterized in that, spray velocity is 60rpm, atomisation pressure 2.0bar；It is dry
Wind turbine frequency is 35-45Hz when dry, and 30-70 DEG C of temperature of charge, 60-100 DEG C of inlet air temperature, drying to moisture is 1.0-3.0%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810317137.8A CN108514550A (en) | 2018-04-10 | 2018-04-10 | Solid drugs and preparation method thereof containing Abiraterone acetate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810317137.8A CN108514550A (en) | 2018-04-10 | 2018-04-10 | Solid drugs and preparation method thereof containing Abiraterone acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108514550A true CN108514550A (en) | 2018-09-11 |
Family
ID=63431982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810317137.8A Pending CN108514550A (en) | 2018-04-10 | 2018-04-10 | Solid drugs and preparation method thereof containing Abiraterone acetate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108514550A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115990169A (en) * | 2022-12-23 | 2023-04-21 | 华中药业股份有限公司 | Prednisone acetate pharmaceutical composition and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102743393A (en) * | 2012-07-27 | 2012-10-24 | 海南盛科生命科学研究院 | Medicinal composition containing abiraterone acetate and preparation technology thereof |
| CN103446069A (en) * | 2012-05-29 | 2013-12-18 | 重庆医药工业研究院有限责任公司 | Oral solid composition of abiraterone and preparation method thereof |
| CN104069075A (en) * | 2013-03-26 | 2014-10-01 | 南京卡文迪许生物工程技术有限公司 | Abiraterone acetate tablet and preparing method thereof |
| CN104138359A (en) * | 2013-05-06 | 2014-11-12 | 扬子江药业集团上海海尼药业有限公司 | Preparing method of zofenopril calcium tablet |
| CN104138360A (en) * | 2013-05-06 | 2014-11-12 | 扬子江药业集团上海海尼药业有限公司 | Preparing method of bevantolol hydrochloride tablet |
-
2018
- 2018-04-10 CN CN201810317137.8A patent/CN108514550A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446069A (en) * | 2012-05-29 | 2013-12-18 | 重庆医药工业研究院有限责任公司 | Oral solid composition of abiraterone and preparation method thereof |
| CN102743393A (en) * | 2012-07-27 | 2012-10-24 | 海南盛科生命科学研究院 | Medicinal composition containing abiraterone acetate and preparation technology thereof |
| CN104069075A (en) * | 2013-03-26 | 2014-10-01 | 南京卡文迪许生物工程技术有限公司 | Abiraterone acetate tablet and preparing method thereof |
| CN104138359A (en) * | 2013-05-06 | 2014-11-12 | 扬子江药业集团上海海尼药业有限公司 | Preparing method of zofenopril calcium tablet |
| CN104138360A (en) * | 2013-05-06 | 2014-11-12 | 扬子江药业集团上海海尼药业有限公司 | Preparing method of bevantolol hydrochloride tablet |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115990169A (en) * | 2022-12-23 | 2023-04-21 | 华中药业股份有限公司 | Prednisone acetate pharmaceutical composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110650730A (en) | Vitamin D analogue preparation and preparation method thereof | |
| CN102321142A (en) | Abiraterone acetate crystal form and preparation method thereof | |
| CN109125276A (en) | A kind of pharmaceutical composition and preparation method thereof of Abiraterone acetate tablet | |
| CN105412026B (en) | Acotiamide hydrochloride hydrate piece and preparation method thereof | |
| CN105343028B (en) | A kind of pharmaceutical composition of Norfloxacin and preparation method thereof | |
| CN112603900A (en) | Solid preparation containing [ (4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl) -amino ] -acetic acid | |
| CN106913529A (en) | A kind of preparation method of HKI-272 or its officinal salt pharmaceutical composition | |
| CN104434845B (en) | A kind of solid pharmaceutical preparation for including the western croak of Leo | |
| CN110354086B (en) | Preparation method of candesartan cilexetil tablets | |
| CN108514550A (en) | Solid drugs and preparation method thereof containing Abiraterone acetate | |
| TW200906397A (en) | Process for preparing pramipexole dihydrochloride tablets | |
| CN111214456A (en) | Voriconazole dry suspension and preparation method thereof | |
| CN102793658A (en) | Matrix-type preparation containing mycophenolic acid or mycophenolic acid salt and coated tablet thereof | |
| CN106913544B (en) | A kind of Gefitinib tablet of Fast Stripping and preparation method thereof | |
| CN106265548A (en) | A kind of preparation method of carbamazepine dispersible tablet | |
| CN111346064B (en) | Rivaroxaban tablet and preparation method thereof | |
| CN114557975A (en) | Sustained release tablet containing exemestane, process and use | |
| CN103655499B (en) | Stable X-crystal-shaped agomelatine tablet and preparation method thereof | |
| CN103690499B (en) | Stable crystalline form I agomelatine tablets and preparation method thereof | |
| CN108261409A (en) | A kind of combination of oral medication of dabigatran etcxilate and preparation method thereof | |
| CN105998012A (en) | Diabetes treatment pharmaceutical composite and preparation method thereof | |
| CN107405342A (en) | A kind of solid composite medicament containing diamine derivative or its salt | |
| WO2019230937A1 (en) | Solid oral dosage form having excellent dissolution properties | |
| CN104288113A (en) | Azilsartan pharmaceutical composition and preparation method thereof | |
| CN110169956A (en) | A kind of sitafloxacin microcapsule formulation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180911 |
|
| RJ01 | Rejection of invention patent application after publication |